Candida lusitaniae causing fatal meningitis

P.S.A. Sarma¹, P. Durairaj² and A.A. Padhye³

Departments of ¹Medicine and ²Microbiology, Jawaharlal Nehru Hospital & Research Centre, Bhilainagar-9, Madhya Pradesh 490006, India and ³Division of Mycotic and Bacterial Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, US Department of Health and Human Services, Atlanta, Georgia, USA

Summary: Fatal meningitis due to Candida lusitaniae in a 35 year old previously healthy man is described. C. lusitaniae is an opportunistic fungal pathogen reported infrequently in the English literature. This is the third case report of meningitis and the first fatal infection in an adult from Central India due to C. lusitaniae known to the authors.

Introduction

Candida lusitaniae van Uden et do Carmo-Sousa, originally isolated from the gastrointestinal tracts of warm-blooded animals,¹ has recently been found to colonize rarely the gastrointestinal, respiratory and urinary tracts and skin of hospitalized patients.² This organism shares morphological, biochemical and other characteristics with other species of the genus Candida, such as C. tropicalis and C. parapsilosis.³ More recently, C. lusitaniae has been recovered from a variety of human clinical specimens such as respiratory and genitourinary secretions, stool, blood, pleural fluid, kidneys, lungs, bone⁴,⁵ and cerebrospinal fluid.⁶⁷

The reports of a premature infant⁷ and a 2 year old white male⁶ with C. lusitaniae sepsis and meningitis are the only examples of meningeval infection caused by this organism, of which we are aware. Blinkhorn et al.⁸ in their review did not include any additional patient with this form of C. lusitaniae disease. The present report describes a third case of meningitis and a first fatal case caused by this emerging pathogen in a non-white patient from central India.

Case report

A 35 year old man was admitted as an emergency to the Jawaharlal Nehru Hospital and Research Centre, Bhilainagar, Madhya Pradesh, India, with a 8 day history of fever and unconsciousness of one day, weakness and anorexia. His past medical history included hernia repair surgery at the age of 5 years. The patient had no history of any recent illness. Physical examination on admission revealed a febrile man in a poor general condition. He had a soft neck, with no signs of meningism. A bilateral paracentral subcutaneous hemorrhage, right subconjunctival hemorrhage, bilateral penile and phallic edema and right sided periorbital edema were noted on examination. His spleen was palpable 3 cm below the costal margin. His heart sounds were normal. The patient was treated with intravenous fluids and was monitored in the Intensive Care Unit. His condition did not improve and he died on day 8 of admission.

References


day’s duration and three episodes of generalized convulsions. The patient had no history of medical illness prior to hospitalization. He had received intravenous (i.v.) ciprofloxacin and gentamicin for 3 days from a private medical practitioner. On examination, he was found to be unconscious, febrile (38.3°C) and mildly dehydrated. The spleen had enlarged 2 cm below the costal margin and liver 2 cm below the right costal margin. He had no significant lymphadenopathy. Signs of meningeal irritation were present and plantar reflexes were bilateral extensor. There were no cranial nerve palsy or motor deficits. His haemogloblin was 12.3 g/dl, white cell count 11.9 × 10⁹/l (neutrophils 76%), and platelets 204 × 10⁹/l. The hepatic and renal function tests were normal. A sickling test was negative and urinalysis, skull and chest X-rays were normal. Lumbar puncture yielded haemorhagic cerebrospinal fluid (CSF) with white cells of 500 × 10⁹/l (neutrophils 70% and mononuclears 30%) and red cells of 25 × 10⁹/l. The concentration of CSF glucose was 1.96 mmol/l (serum glucose 5.32 mmol/l) and that of protein was 105 mg/dl. No bacteria were seen on a Gram-stained smear of CSF sediment. His blood, CSF and urine cultures grew no bacteria. He received i.v. fluids, i.v. chloramphenicol, gentamicin and crystalline penicillin. Two days later the CSF grew a yeast subsequently identified as C. lusitaniae, which was susceptible to amphotericin B and flucytosine tested at the Mycotic Diseases Branch, Centers for Disease Control, Atlanta, USA.

The colonies of the organism were cream-coloured, soft, smooth and glistening. After 3–4 days of growth in glucose–yeast-extract–peptone water at 25°C, cells of C. lusitaniae were subglubose to ovoid with a size range of 1.5–5 μm × 2.5–10 μm. The pseudomycelium on cornmeal agar was composed of branched chains of slender, often curved pseudohyphae that bore short chains and clusters of blastoconidia.9 The separation of C. lusitaniae from similar yeast such as C. parapsilosis, C. tropicalis, C. f Bedschusii and C. obtusa is necessary.8 Tests used for differentiation included fermentation of cellobiose, glucose, galactose and trehalose, lack of growth over cyclohexamide-containing media and negativity for urease production.7,8 The yeast was appropriately identified with the API 20C system (Analytab Products, Plainview, NY, USA).8

Over the next day, the neurological condition remained the same with no improvement. He remained febrile and within 34 hours of hospitalization, the patient expired due to sudden cardiopulmonary arrest. Postmortem examination was refused but a postmortem sample of brain was scanty and revealed no evidence of tissue invasion in histological sections stained with haematoxylin and eosin and Gomari’s Methanamine Silver.

Discussion

Pappagianis et al.4 and Holzschu et al.10 published the first documented case of opportunistic infection caused by C. lusitaniae in a patient with leukaemia and also demonstrated the capacity of this strain to develop resistance to amphotericin B. Merz and Sandford11 reported a polyene-resistant variant of C. tropicalis that was later reidentified as C. lusitaniae.

During the last 13 years after the publication of the first documented case of opportunistic infection caused by C. lusitaniae,4 18 cases have been reported in the English literature and over 100 clinical isolations of C. lusitaniae have been described.8,12 Of the 18 cases reported until now, 13 patients were adults,8 two were neonates,5,7 and one was a teenager.11 Most patients with C. lusitaniae fungaemia were immunocompromised, usually owing to an underlying malignancy2–4,6,12–15 and transplantation.13 Not surprisingly, the use of broad-spectrum antibiotics (14 of 18 patients), the presence of an intravascular catheter (nine of 18), the use of cytotoxic or corticosteroid therapy (nine of 18), and the occurrence of granulocytopenia (five of 18) were noted frequently, while the presence of diabetes mellitus was noted infrequently (one of 18).13 Total parenteral nutrition, a known risk factor for the development of fungaemia caused by other candida species16 could not be assessed as a predisposing factor because of a lack of documentation in previous reports. However, Terreni et al.17 reported C. lusitaniae septicemia in a 34 year old male undergoing home i.v. hyperalimentation and suggested hyperalimentation as one of the predisposing factors which might have contributed to their patient’s acquisition of C. lusitaniae fungaemia. In addition, there has been at least one reported instance of transient septicemia in which the yeast was isolated only once and no treatment was instituted.18

The first successful therapy of C. lusitaniae fungaemia was reported in 1985.19 Before 1989, with the exception of a case of transient fungaemia not requiring therapy,19 all reported infections with C. lusitaniae required antifungal therapy,3,6,8,13,17,19,20 and resistance to amphotericin B played a role in the fatal17 outcome of the disease.2,4,11,14,20

Our patient received broad-spectrum antibiotics (ciprofloxacin and gentamicin) for 3 days prior to hospitalization. We believe that broad-spectrum antibiotic usage was the predisposing factor in our patient who was otherwise healthy causing immunocompromise contributing to the development of fatal C. lusitaniae meningitis.

To date, out of more than 100 clinical isolations of C. lusitaniae reported in the English literature,8,12 three-quarters of the isolates have been recovered from the blood, urine or respiratory tract.8 Positive
extravascular cultures in patients with *C. lusitaniae* fungaemia reported in the English literature were obtained mostly from the respiratory tract and pharynx, stool, urine, soft tissue, skin, vagina or intravascular catheter. Only two isolates of *C. lusitaniae* have been recovered from CSF. Our case report describes the recovery of the third isolate of *C. lusitaniae* from CSF.

Until now, human infections due to *C. lusitaniae* have been reported from North America and Europe. Our report indicates that *C. lusitaniae* is not necessarily restricted geographically to the developed world. It is important that the clinical laboratory recognizes this emerging pathogen when it is isolated from clinical material, especially from individuals already debilitated by malignant disease, sepsis, cytotoxic and steroid therapy, usage of broad-spectrum antibiotics and diabetes mellitus. Thus it appears that *C. lusitaniae* is similar to other yeast species in its ability to colonize individuals and cause opportunistic infections in compromised hosts. This species does not seem to differ from other medically important yeasts in the development of resistance to amphotericin B *in vivo*. In conclusion, *C. lusitaniae* should be considered as an opportunistic pathogen in both immunocompromised adults and children when isolated in the appropriate clinical setting, with no prejudice to geographical localization and restriction.

**Acknowledgements**

We thank the Director, Medical & Health Services, Bhilai Steel Plant, for permission to use hospital records and Dr (Mrs) S. Diwan and Dr M. Bhatta for their invaluable help.

**References**


Candida lusitaniae causing fatal meningitis.

P. S. Sarma, P. Durairaj and A. A. Padhye

Postgrad Med J 1993 69: 878-880
doi: 10.1136/pgmj.69.817.878

Updated information and services can be found at:
http://pmj.bmj.com/content/69/817/878

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/